Oncovision is a leading provider of innovative medical imaging devices used by surgeons, radiologists, oncologists and nuclear physicians for the diagnosis and treatment of cancer. Oncovision has grown into a dynamic brand in a technologically competitive, high-growth industry. Oncovision has offices in Boston, USA and Valencia, Spain and sells its products in over 30 markets through a combination of direct sales and distributors. Through a strong internal pipeline, Oncovision boasts a clinical and preclinical product line. Clinical product line includes market-leading Sentinella, a unique intra-operative Gamma Camera and the revolutionary Mammi PET, a breast cancer diagnostic device capable of visualising lesions of less than 2mm and quantifying tumor activity. Oncovision completes its portfolio with Wprobe, the gold standard in radioguided surgery. Oncovision has distinguished itself through the ability to successfully develop and bring to the market innovative products to generate significant benefits on patients, and is committed to continue that trend. Also, the company plans to bring forth technical and clinical solutions for an accurate diagnosis and treatment of cancer, providing the highest-quality, best-performing products. Our values are the beliefs we all share, that drive our company personality, culture, and priorities. They provide a framework for making decisions and the how Oncovision employees are expected to conduct themselves in a professional and responsible manner. The Oncovision Code of Conduct contains important information and resources to guide you in conducting business legally, ethically, and responsibly in accordance with our shared values.
Build a best in class international organization to achieve leadership in focused markets, leveraging innovative imaging technologies that result in improved patient quality of life and healthcare professionals experience.
We change the practice of medicine with solutions that speed detection, diagnosis and treatment while improving patient lives care. Transforming the cure of cancer, through the creation of new standard diagnostic tests and treatment in multimodal molecular vision technologies for surgery, diagnosis, intervention and advanced research with clinical and economic advantages.